

Atoms for Peace and Development

Ile Julia الوكالة الدولية للطاقة الذرية 国际原子能机构 International Atomic Energy Agency Agence internationale de l'énergie atomique Международное агентство по атомной энергии Organismo Internacional de Energia Atómica

Vienna International Centre, PO Box 100, 1400 Vienna, Austria

Phone: (+43 1) 2600 • Fax: (+43 1) 26007

Email: Official.Mail@iaea.org • Internet: https://www.iaea.org

In reply, please refer to: SP-TC-RER6041-2500775 Dial directly to extension: (+43 1) 2600-25981

2025-09-11

Subject: TC Sponsored Participation on Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6, from 04 to 05 December in Vienna, Austria.

Dear National Liaison Officer / National Coordinator,

National Liaison Officers/National Coordinators

I am pleased to inform you that the International Atomic Energy Agency (IAEA) will sponsor the participants to attend EANM/ESMIT event on Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6, under the IAEA technical cooperation project **RER6041**, "Enhancing and Harmonizing Nuclear Medicine and Diagnostic Imaging Capabilities".

The purpose of the event is to understand breast cancer as a heterogeneous disease, its characteristics and evolution; to define the role of nuclear medicine techniques in different clinical settings and to know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment.

Selection of participants will be in accordance with IAEA procedures. Member States are strongly encouraged to identify women participants.

The IAEA will provide non-local participants with a round-trip air ticket based on the most direct and economical route between the airport nearest the participant's residence and Vienna or a travel allowance to purchase an air ticket. Travel details will be agreed with the participants upon receipt of their official nomination. Participants will also receive an allowance from the IAEA sufficient to cover their costs of lodging, daily subsistence and miscellaneous expenses for the duration of the event in line with IAEA rules and procedures.

We would appreciate receiving your country's nominations by **04 November 2025** through the IAEA's InTouch+ platform (https://Intouchplus.iaea.org). Should this not be possible, applicants may download the Nomination Form for the course from the IAEA's webpage. Completed forms must be endorsed by the relevant government authority and may be sent to the IAEA, preferably by email to Official Mail-IAEA Mail address Official.Mail@iaea.org, with copy to Ms Sibel Unlu s.unlu@iaea.org and Ms Angie Mieses A.Mieses-Concepcion@iaea.org. Please be advised that late nominations or replacements of participants after the closing date for nominations will not be accepted.

We look forward to receiving your early response.

Yours sincerely,

Sibel Unlu

Programme Management Officer

Division for Europe

filed

Department of Technical Cooperation

Enclosure: Information Sheet



TC Sponsored Participation on Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6 under the Regional TC Project RER/6/041

Event Number	SP-TC-RER6041- EVT2500775
Event Title	TC Sponsored Participation on Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6
Location	Vienna, Austria
Date	04 to 05 December 2025
Nomination Deadline	04 November 2025
Event Information	Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women, being the fourth globally regardless of gender. By 2040, breast cancer is predicted to increase to over 3 million new cases and 1 million deaths per year. During this course, the highlights from the consensus reached during the multidisciplinary EANM Focus Meeting 6 about Nuclear Medicine diagnostics and therapeutics possibilities will be comprehensively presented and discussed in a close way between the faculty and attendees. LEARNING OBJECTIVES To understand breast cancer as a heterogeneous disease, its characteristics and evolution; To define the role of nuclear medicine techniques in different clinical settings (initial staging, assessing therapy response, and detecting recurrence); To know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment; To discuss future diagnostic and treatment approaches with radiopharmaceuticals;
Organizer	European School of Multimodality Imaging & Therapy Link: Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6 - The
	European School of Multimodality Imaging & Therapy (ESMIT)
Selection Criteria	Nuclear Medicine physicians, Radiologists, Medical Oncologists, Radiation Oncologists, Medical students, Residents, Nurses, Nuclear Medicine technologists and Radiographers.